Skip to main content
OpenTrials

Clinical trial condition

Neuroectodermal Tumors

Explore clinical trials studying Neuroectodermal Tumors. Study availability and eligibility vary by location and protocol.

5,994 public trials 1,209 recruiting studies
Refine in advanced search Browse all conditions

Neuroectodermal Tumors trial results

Active, Not Recruiting

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

NCT03749187

Conditions
Astrocytoma, Glioblastoma, Glioma, +16 more
Locations
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • University of California, San Francisco San Francisco, California, United States
  • Yale University New Haven, Connecticut, United States
  • Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
View Trial Details
Active, Not Recruiting

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

NCT04417621

Conditions
Melanoma, Neoplasms, Neoplasms by Histologic Type, +9 more
Locations
  • The Angeles Clinic and Research Institute Los Angeles, California, United States
  • UCSF Medical Center San Francisco, California, United States
  • Florida Cancer Specialists Fort Myers, Florida, United States
  • H Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
View all 36 locations
View Trial Details
Active, Not Recruiting

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

NCT05484622

Conditions
Astrocytoma, Glioma, Neoplasms, +7 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • University of California, Los Angeles (Site: 840113) Los Angeles, California, United States
  • University of California, San Francisco (Site: 840149) San Francisco, California, United States
  • University of Colorado Aurora, Colorado, United States
View all 17 locations
View Trial Details
Active, Not Recruiting

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

NCT03999749

Conditions
Melanoma, Neoplasms, Neoplasms by Histologic Type, +9 more
Locations
  • The Angeles Clinic Los Angeles, California, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • NYU Langone Health New York, United States
View Trial Details

Related conditions